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Chloride transport proteins play critical roles in inflammatory airway diseases, contributing to the detrimental aspects of mucus
overproduction, mucus secretion, and airway constriction. However, they also play crucial roles in contributing to the innate
immune properties of mucus and mucociliary clearance. In this review, we focus on the emerging novel roles for a chloride
channel regulator (CLCA1), a calcium-activated chloride channel (TMEM16A), and two chloride exchangers (SLC26A4/pendrin
and SLC26A9) in chronic inflammatory airway diseases.

1. Introduction
The chronic inflammatory airway disease, asthma, and chronic
obstructive pulmonary disease (COPD) are significant causes
of morbidity and mortality in children and adults. Asthma
affects over 300 million people worldwide, and the prevalence
is increasing among all demographics. COPD is currently
the third leading cause of death in USA. These diseases
are hallmarked by a Th2-mediated inflammatory response
which drives the three pathologies that contribute to airway
obstruction in these diseases: chronic inflammation; airway
muscle constriction due to airway hyperreactivity (AHR);
and mucus overproduction due to mucous cell metaplasia
(MCM). A central feature of these diseases is production
of the inflammatory cytokines IL-4 and IL-13, which drive
MCM and contribute to AHR.
The inflammatory signaling upregulates the expression
of hundreds of proteins in the airway epithelia. A number

of these proteins have roles in anion transport across membranes, including chloride channels, channel regulators, and
transporters. The identity, function, and elucidated mechanism of action of these proteins have lagged behind their
cation channel counterparts. However, recent advances in
several technologies, including high throughput screening,
have made it possible to consider the development of specific
inhibitors and activators for these classes of proteins [1].
The development of such therapeutics, however, requires an
intimate knowledge of the roles these proteins play in airway
homeostasis and mucociliary clearance. Anion channels play
very crucial roles in mucus function. Mucus is composed of
97% water and 3% solids, with the main solid component
being the mucin proteins [2]. Mucin proteins are secreted in a
dehydrated form and require anion channel activity to instill
chloride and bicarbonate ions that ensure proper salination,
hydration, and pH of the mucus gel layer. Proper control of
this is crucial as is exemplified by the disease cystic fibrosis

2
(CF), which is caused by loss of function mutations to the
chloride channel cystic fibrosis transmembrane conductance
regulator (CFTR) that produces thick, sticky mucus deficient
in mucociliary clearance or innate antimicrobial properties
[3].
Here we discuss what is currently known about the
function of four exciting, new, and emerging proteins affecting anion channel activity in inflammatory airway epithelia:
a chloride channel regulator (CLCA1), a calcium-activated
chloride channel (TMEM16A), and two chloride exchangers
(SLC26A4/pendrin and SLC26A9). In particular, we focus
on recently uncovered contributions to airway diseases and
mucus function, in order to answer whether they can be
targeted by inhibitors or activators and whether they should
be.

2. The CLCA Family of Chloride
Channel Regulators
The CLCA family of proteins was originally misidentified
as calcium-activated chloride channels and has long been
associated with chronic inflammatory airway diseases. Their
evolving functional identity and the possible role they play in
these diseases have only recently been elucidated.
2.1. CLCAs: Association with Chronic Inflammatory Airway Diseases. Asthmatic inflammation results from a Th2mediated mechanism, where the cytokines IL-4 and IL-13
bind their receptors and activate the transcription factor
STAT6 to drive inflammation and mucus overproduction in
the airways [4, 5]. In mouse models of both allergic and
respiratory virus induced-asthma, CLCA1 (previously known
as mCLCA3 or gob-5) expression has been solidly linked to
IL-13 driven MCM [6, 7] and controversially linked to AHR
[6], both hallmarks of asthma and COPD. Similar results were
observed in vitro with the human pulmonary mucoepidermoid cell line NCI-H292, in which expression of the protein
significantly increased mucin gene MUC5AC expression and
subsequent mucus production [8, 9], implying that CLCA1
can drive MCM. Studies using Clca1−/− mice, however, have
failed to show reduced response to IL-13 stimulation, as these
mice showed the same phenotype as wild-type (WT) mice
[7, 10]. Other members of the family, particularly CLCA2 and
potentially CLCA4A and CLCA4B, have also been observed
to be upregulated and to induce and colocalize with the
inflammatory mucin protein, MUC5AC [7]. These results
indicate a possible functional redundancy between members
of the mouse CLCA family, which is unlikely to translate to
human biology, as there are only three human CLCA proteins,
compared to the seven mouse CLCA proteins [11] (Figure 1).
Of the three human CLCA proteins, CLCA1 has been
identified as a potential biomarker of inflammation and
MCM in the airways [12] and suggested as a potential drug
target for treatment of asthma and COPD. Similar to mouse
CLCA1, overexpression of human CLCA1 in NCI-H292 cells
increases MUC5AC expression and mucus levels [6, 8, 9].
Its expression is upregulated in primary cell models of IL13 driven MCM and siRNA-mediated knockdown of CLCA1
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prevents IL-13-driven mucus overproduction [9]. These
experimental observations suggest a central role for CLCA1
function in IL-13-mediated MCM (Figure 2). Additionally, it
is highly overexpressed in the airway epithelia of asthmatic
patients [8] and can be found in the bronchoalveolar lavage
fluid (BALF) at high levels [13]. In contrast, other members of
the human CLCA family are not upregulated in response to
IL-13 [8, 9], suggesting that CLCA1 is the sole family member
with an essential role in MCM in human airways.
2.2. The Conceptual Evolution of CLCA Proteins from “Channels” into “Channel Regulators”. The family of CLCA proteins
were first cloned from bovine and murine samples, where
overexpression of these proteins increased Ca2+ -sensitive Cl−
conductance, which led to their initial misannotation as
Ca2+ -activated Cl− channels (CaCCs) [14–16]. In addition,
observations that nonspecific chloride channel blockers, such
as niflumic acid and DIDS, seemed to reduce both currents
and the mucus production [17] erroneously supported this
hypothesis. However, modern bioinformatics algorithms and
experimental approaches have definitively demonstrated that
CLCA proteins are soluble, secreted proteins that do not
constitute ion channels themselves [13, 18], and subsequent
studies demonstrated that CLCA proteins activate currents
through an endogenous CaCC [18–20]. As a consequence,
the CLCA nomenclature has been updated and the family
is now recognized as Ca2+ -activated Cl− channel regulator
proteins. All members of this family (with the exception of the
likely pseudogenes human CLCA3 and mouse CLCA4C) are
synthesized as full-length proteins and proteolytically cleaved
into two fragments. It has been demonstrated that, for some
of the family members, the cleavage is carried out by a zincdependent matrix metalloprotease-like (MMP-like) domain
located in the N-terminus of the protein [18, 21] (Figure 1).
However, sequence analysis has revealed that all CLCA family
members contain the required MMP active site motif [18];
thus self-cleavage is likely a conserved feature of all CLCAs.
Self-cleavage is required to unmask the N-terminal fragment
of CLCA1, which then interacts with the CaCC [18] (Figure 2).
The molecular identity of this previously unknown CaCC
has been shown to be TMEM16A and the direct interaction
between the channel and the N-terminal fragment stabilizes
and increases the cell surface expression of the channel,
thereby increasing currents [20].
2.3. CLCA1 as a Potential Regulator of Cytokine Expression.
Upstream of CLCA1 expression, the involvement of Th2cytokines IL-4 and IL-13 has been shown in cellular and
animal models as discussed above. The relationship between
CLCA1 and downstream cytokine signaling, however, is still
under investigation. The few articles that do exist report
contradictory observations regarding the role of CLCA1 as
a signaling molecule for cytokine expression. Challenging
Clca1−/− mice with lipopolysaccharide (LPS), Long et al.
observed increased KC (keratinocyte-chemoattractant) levels
in BALF, but no change in MIP-2 (macrophage inflammatory
protein 2) or IL-17 levels in the knockout mice compared
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Figure 1: Domain architecture schematic for human and mouse CLCA proteins. Each row contains the corresponding human and mouse
homologs. Mouse CLCA proteins are labeled according to the recently updated naming commissioned by the Mouse Gene Nomenclature
Committee (MGNC) in order to align the numbering established by the Human Gene Nomenclature Committee and the Rat Genome
Database. The previously used names for the mouse proteins are shown below the current names and are in italics. Scissors denote
the experimentally determined location of proteolytic cleavage sites [18]. Human CLCA3 and mouse CLCA4C are likely pseudogenes
because they contain premature stop codons. Labels denote the following domains: CAT: matrix-metalloprotease-like catalytic domain;
CYS: matrix-metalloprotease-like cysteine rich domain; vWA: von Willebrand factor type A domain; FnIII: fibronectin type III domain;
TM: transmembrane domain; GPI: glycosylphosphatidylinositol anchor.
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Figure 3: Domain architecture schematic for human TMEM16A. Topology shown is predicted from structure-based alignment to the crystal
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to WT mice [22]. In contrast, Dietert et al. observed significantly decreased levels of IL-17 and CXCL-1 in BALF
from the Clca1−/− mice infected with Staphylococcus aureus
[23]. Using a cellular model of inflammation, Ching et al.
showed that CLCA1-conditioned media increased proinflammatory cytokine (IL-6, IL-8, IL-1𝛽, and TNF 𝛼) mRNA
levels in monocyte cell line U-937 and primary porcine
alveolar macrophages. Immunopurified CLCA1 protein only
increased IL-8 and IL-1𝛽 levels significantly [24]. If such a
regulatory mechanism exists for cytokine expression, modulation of CLCA1 function with small molecules to treat mucus
cell metaplasia might also alter the inflammatory response in
the airways.

3. TMEM16: The First Family of CaCCs
While CaCC conductance was a long-observed phenomenon
in the airways and could be separated from CFTR currents, the molecular identity of the channels responsible for
these currents remained elusive until the late 2000s. The
TMEM16/Anoctamin family was identified in 2008 as the
first bona fide CaCCs [25–27]. However, based on their
electrical and pharmacological characterization, only two
of the ten family members, TMEM16A and TMEM16B,
displayed properties previously observed for CaCCs in the
airways [28, 29], whereas most of the other members function
as lipid scramblases. Of these two, TMEM16A expression has
been verified in airway epithelium and airway smooth muscle
cells [30].

3.1. TMEM16A Is Linked to Chronic Inflammatory Airway Diseases. The predicted topology for TMEM16 family members
is based on the recent landmark crystal structure of the fungal
Nectria haematococca TMEM16 (nhTMEM16) which has 10
transmembrane domains instead of the previously predicted
8 (Figure 3) [31]. The purified and reconstituted protein,
which was shown to be a homodimer [32], constitutes a
channel on its own and does not require other proteins to be
active [33]. While the Ca2+ sensitivity of the channel is well
documented [31, 34, 35] and the protein directly binds Ca2+ ,
the possible involvement and mechanism of interaction with
calmodulin as a calcium sensor and binding partner are still
controversial [35–37].
Much like CLCA1, expression of TMEM16A is upregulated by IL-4/IL-13 stimulation [38–41]. Upon upregulation,
TMEM16A colocalizes to the apical plasma membrane of
goblet cells along with the mucin MUC5AC [41–43]. It
is expressed in airway smooth muscle cells and has been
shown to play a role in AHR [42]. Additionally, inhibitors
of TMEM16A have been shown to block mucus secretion
[42, 44] whereas small molecule activators increase secretion
[45].
3.2. The Potential for Targeting CLCA1 and TMEM16A in
Chronic Inflammatory Airway Diseases. CLCA1 is a promising therapeutic target for asthma and COPD, as it is the only
member of its family to be upregulated in models of IL-13
mediated mucus overproduction [9], is a secreted protein
[18], is expressed in goblet cells [7, 9, 16], and associates with
mucin granules [46, 47]. Overexpression of CLCA1 in airway
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epithelium induces MUC5AC expression via a signaling cascade involving the kinase MAPK13, and siRNA-knockdown
of CLCA1 blocks mucus production in these models [9],
implying a critical role for CLCA1 function in inflammatory mucus production. Consistent with these observations,
DNA vaccines [48] and antibodies targeting mouse CLCA1
[49] have displayed some effectiveness in reducing airway
inflammation and MUC5AC levels in mouse asthma models.
Similarly, as mentioned above, TMEM16A inhibitors block
ATP-dependent mucus secretion, suggesting a central role for
this pair in inflammatory mucus overproduction. However, it
should be noted that these small molecules have relatively low
potency and questionable selectivity and these findings need
to be supported by additional experiments to determine the
role TMEM16A plays in mucus secretion [50]. An important
question that currently remains unanswered is what role this
pair of molecules plays in mucociliary clearance. It is well
known that anion channel activity is required for secreted
mucins (MUC5AC and MUC5B) to function properly in a
mucosal immunity and mucociliary clearance capacity [51].
Mucin proteins are secreted in dense, dehydrated granules
and require anion channel passage of chloride and bicarbonate ions to ensure proper hydration, salination, and pH
control [2]. Thus, any therapy targeting anion channel activity
in airway diseases should proceed with caution to avoid
any potential detrimental impacts to mucociliary clearance
and innate mucosal immunological properties. Along these
lines, exploiting the mechanism CLCA1-mediated regulation
of TMEM16A action might be a possible therapeutic route
for CF, utilizing a potential compensatory channel to make
up for loss of CFTR activity [52]. Further along these lines,
TMEM16A has been shown to carry not only chloride ions
but also bicarbonate ions [36]; thus activation of TMEM16A
in the setting of CF could be beneficial to adjust mucus
hydration and pH.

4. SLC26: An Ancient Family with
Unexpected New Roles
Over the last decade the anion exchanger pendrin (PDS,
SLC26A4), once thought to be limited mainly to the inner
ear, kidney, and thyroid, has been found to be upregulated by
inflammatory cytokines in the bronchial epithelium, where
it contributes to the pathogenesis of inflammatory airway
diseases [53–55] and also to the host response to bacterial
infections [56, 57]. Another member of the family, SLC26A9,
is prominently expressed in the airway epithelia, where it
interacts with CFTR to modulate mucus production [58].
The discovery of these crucial roles in lung physiology and
pathophysiology makes these anion transporters intriguing
new biomarkers for airway disease and promising novel
pharmacological targets.
4.1. Pendrin: An Anion Exchanger with Critical Roles in Ear,
Kidney, and Lung Physiology. Pendrin (PDS, SLC26A4) is
a member of the SLC26 family of multifunctional anion
transporters and channels [59, 60]. The eleven mammalian
SLC26 genes encode proteins with cytoplasmic N-termini
and C-termini flanking a transmembrane core of unknown
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structure, predicted to span the lipid bilayer 10 to 14 times
(Figure 4). Mutagenesis, homology modeling, and molecular
dynamics simulation data are consistent with the hypothesis
that the SLC26 transmembrane fold consists of two nesting,
inverted repeats of 5–7 helices, resembling that of the CLC
Cl− /H+ antiporter channel proteins [61, 62] and the recently
solved three-dimensional structure of SLC26Dg, a bacterial
H+ -coupled fumarate symporter, has clarified this [63]. It has
been suggested that SLC26 proteins organize in functional
homodimers or homotetramers [64], though each subunit is
thought to constitute an independent translocation pathway.
The C-terminal cytoplasmic region of all SLC26 proteins
includes a sulfate transporter and antisigma factor antagonist
(STAS) domain (Figure 4), which has been implicated in
nucleotide binding and hydrolysis [65]. SLC26A4, or pendrin, functions as an electroneutral exchanger of Cl− , HCO3 − ,
I− , NO3 − , formate, SCN− , and other monovalent anions. It is
expressed in cochlear epithelial cells of the spiral prominence,
in root cells, in spindle cells of the stria vascularis, in
epithelial cells of the endolymphatic sac, and in epithelial
cells surrounding the hair cells of the saccule, utricle, and
ampulla [66]. Additionally, pendrin is expressed in the apical
membrane of thyrocytes [67, 68], renal collecting duct Type
B intercalated cells [69], salivary gland cells [70], and airway
epithelia [53].
Pendrin function is important in several settings. In the
inner ear, pendrin helps maintain Cl− and HCO3 − homeostasis, which is crucial for normal hearing and for the development of bony structures such as the cochlea and the vestibular
aqueduct [71]. In the thyroid gland, pendrin contributes I−
to the follicle for thyroxine biosynthesis [72], and in the
cortical collecting duct the transporter is implicated in Cl−
reabsorption through functional coupling with the epithelial
Na+ channel ENaC and the Na+ -dependent Cl− /HCO3 −
exchanger NDCBE/SLC4A8 [73]. Most interestingly, it has
been shown that in the bronchial epithelium pendrin mediates an increase in Cl− /SCN− exchange in response to IL-4
stimulation [74] to provide SCN− substrate to lactoperoxidase
for the synthesis of hypothiocyanite (OSCN− ), a molecule
with antimicrobial properties [75], and this underscores the
emerging role of pendrin in innate airway defense mechanisms (Figure 5).
4.2. Pendrin and the Pathogenesis of Inflammatory Lung
Disease: Too Much of a Good Thing? Pendrin was first identified by positional cloning as the disease gene for Pendred
syndrome (OMIM number 247600), an autosomal recessive
condition characterized by deafness with enlargement of
the vestibular aqueduct, complex abnormalities in cochlear
structure, and variably penetrant euthyroid goiter [76–78].
Pendrin is also implicated in DFNB4, an autosomal recessive
form of nonsyndromic deafness [79]. SLC26A4 mutations
that are clinically associated with Pendred syndrome cause
complete loss of transport function when studied in heterologous expression systems, mostly due to retention in various intracellular compartments, whereas those exclusively
associated with DFNB4 have residual transport activity [80].
In recent years, pendrin gain of function, mainly due to
increased surface expression, has been linked to respiratory
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diseases including bronchial asthma, COPD, and rhinovirus
infection, rhinitis, and chronic rhinosinusitis [54, 55, 81–86].
The association between pendrin and inflammatory airway disease was first proposed in 2005, when it was observed
that pendrin expression was upregulated in three different
murine asthma models, including transgenic overexpression
of IL-13 in lung [83]. Later, it was reported that induction
of asthma or COPD in mice by inhalation of ovalbumin or
elastase, respectively, resulted in increased pendrin expression; direct overexpression of pendrin in the lung led to
increased mucus production and secretion and neutrophilic
infiltration [86]. In subsequent works, the link between
inflammatory cytokines, in particular IL-4 and IL-13, and
pendrin overexpression has been cemented [81, 85, 87],
and in a recent study SLC26A4 was identified as the most
upregulated gene in human asthmatic bronchi [88]. A major
downstream effect of IL-4 and IL-13 signaling is the activation of the signal transducer and activator of transcription
6 (STAT6). Following ligand-receptor binding, associated
Janus kinases (JAKs) activate the receptor, allowing STAT6
to then be recruited and activated by phosphorylation. Once
phosphorylated, STAT6 homodimerizes and translocates to
the nucleus where it regulates the transcription of target genes
via binding to N4 interferon-𝛾 activated sequences (N4 GAS)
in the promoter region [89]. The pendrin promoter contains
at least one N4 GAS motif, and STAT6 has been shown to
bind this sequence in vitro, thus suggesting that increases in

pendrin promoter activity via STAT6 represent at least one
mechanism by which IL-4 and IL-13 increase pendrin activity
[87]. Cytokines other than IL-4 and IL-13 may be responsible
for increases in pendrin expression; IL-1𝛽, a macrophagesecreted cytokine involved in the immunopathogenesis of
asthma and COPD, has also been shown to increase pendrin
levels in rodent and human bronchial epithelial cells [74, 90].
Signaling through IL-4/IL-13 mediates airway hyperresponsiveness, eosinophilic inflammation, mucus cell metaplasia and mucus overproduction, subepithelial fibrosis, and
increased viscosity of the airway surface liquid (ASL), all of
which are common to bronchial asthma and COPD [91].
Pendrin may play a major role in the pathogenesis of asthma
or COPD by regulating some of these responses, in particular
ASL thickness and mucus production (Figure 5). In lung
epithelial cells, reabsorptive Na+ transport through ENaC is
suppressed whereas secretory Cl− transport through CFTR
and CaCCs is stimulated, which collectively results in a
net secretory phenotype whereby water osmotically flows
into the lumen and ASL viscosity decreases. On the other
hand, pendrin imports Cl− in exchange for other anions,
and thus an IL-4/IL-13-mediated increase in pendrin activity
may shift the equilibrium towards a reabsorptive phenotype,
resulting in the osmotic flow of water into the interstitium
and the thinning of the ASL [85]. In asthmatic mice, mucus
overproduction is accompanied by an increased pendrin
expression at the apical surface of bronchial epithelial cells,
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and in pendrin overexpression cell models, production of
MUC5AC, a major mucus protein in asthma and COPD
patients, is increased [86]. In mice, pendrin overexpression
is also accompanied by neutrophil-dominant inflammation,
suggesting that, in this system, mucus production may be
induced not only by a direct effect of pendrin on airway
epithelial cells, but also by an indirect effect of pendrin by
recruiting inflammatory neutrophils [86].
In bronchial epithelial cells, IL-4/IL-13 signaling upregulates the expression of CLCA1 [9], CFTR [92], and pendrin
[87], whereas it downregulates the expression of the 𝛽
and 𝛾 subunits of ENaC. Because upregulation of certain
proteins, such as pendrin, might aggravate asthma or COPD
symptoms, whereas the downregulation of ENaC and the
downregulation of CLCA1 might be protective (Figure 5), it
is unsurprising that pharmacological strategies aimed at the
blocking of the IL-4/IL-13 pathway are not as successful as
they were anticipated to be [93]. Selective inhibition of pendrin could be an intriguing new strategy for asthma/COPD

therapy, but as noted above, pendrin contributes to the
secretion of SCN− , a substrate of lactoperoxidase for the
production of the protective, antimicrobial OSCN− [74], and
this should be taken into account when exploring novel
treatment avenues.
4.3. The Next Frontier: Pendrin and Infectious Lung Disease.
Most recently, pendrin has been implicated in the IL-17Adependent host inflammatory response to bacterial airway
infections (Figure 5) [56, 57]. IL-17A is critical for the
immune response of the lung to infectious bacteria, for example, Haemophilus influenzae, Staphylococcus aureus, Klebsiella
pneumoniae, and Bordetella pertussis [94]. The latter is the etiologic agent of whooping cough, or pertussis disease, which
is a resurgent condition of great clinical concern as it can
progress to pulmonary inflammation and death in infants and
for which there is no effective treatment [95]. Pertussis toxin
(PT), the virulence factor of B. pertussis, undermines the host
immune system by inhibiting macrophage and neutrophil
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responses, suppressing the production of antibodies against
the bacteria, and inducing proinflammatory cytokines, in
particular IL-17A [96]. One of the most highly upregulated
genes in association with PT activity is SLC26A4 [97, 98], and
pendrin is upregulated in human bronchial epithelial cells
exposed to IL-17A [56]. In the lungs of B. pertussis-infected
mice there is an increase in pendrin levels that is concomitant
with an increase in IL-17A but not in IL-4/IL-13 levels, and
pendrin upregulation is significantly hampered in Il-17anull mice [57]. Other host factors may be involved in PTdependent upregulation of pendrin, such as IL-1𝛽 and IFN-𝛾,
as both are upregulated during B. pertussis infection and have
been linked with pendrin upregulation [85, 98, 99]. Taken
together, these recent advances suggest that the upregulation
of pendrin, with its associated inflammatory pathology, is a
major mechanism of virulence for the pertussis toxin and
position pendrin as a potential novel therapeutic target for
the treatment of whooping cough.
4.4. SLC26A9: A Novel CFTR Regulator. SLC26A9 is another
member of the SLC26 family of anion exchangers and
channels. It is robustly expressed in apical airway epithelia
[100] and gastric parietal cells [101] and to a lesser extent in
the kidney, brain, and reproductive tracts [59, 102–104]. The
function of SLC26A9 is still unclear: it has been described as
a Cl− channel with a small degree of bicarbonate transport
[104], a Cl− channel or a Cl− /HCO3 − exchanger [105, 106].
One group reported increased Cl− conductance particularly
in high bicarbonate conditions [107], and others have found
that SLC26A9 activity is coupled to Na+ transport [58, 103,
108]. Like other members of the family, SLC26A9 is predicted
to span the membrane 14 times, and it contains a STAS
domain followed by a PSD95-Dlg1-Zo-1 (PDZ) domain in
the C-terminal cytoplasmic region (Figure 4) [59, 109]. Two
groups propose that SLC26 proteins, including SLC26A9,
interact with CFTR initially via their PDZ domains [110,
111]. This is followed by a stronger interaction between
the CFTR R domain and the SLC26 STAS domain, which
is enhanced by PKA-dependent phosphorylation of the R
domain [111–113]. The interaction between SLC26A9 and
CFTR has been described in multiple studies. However,
whether the interaction is stimulatory or inhibitory is still
controversial and may be cell type-dependent [108, 114].
Not much is known about the regulation of SLC26A9, but
WNK kinases, also known to regulate other transporters
and channels involved in osmoregulation, have been shown
to inhibit SLC26A9 activity via interaction with the STAS
domain [109]. Though the influence of SLC26A9 on CFTR
has been reported, the reciprocal interaction is less clear.
Multiple groups have described CFTR regulation of SLC26A9
activity and expression, but the results are not consistent
[58, 114–118]. Evidence of CFTR and SLC26A9 coexpression
has been found in the lung, trachea, stomach, and sweat gland
[119].
Due to its high expression in the lung, numerous studies
have investigated the role of SLC26A9 in lung disease.
Anagnostopoulou and colleagues [120] first reported that
SLC26A9 activity is responsible for increased constitutive
Cl− current under Th2 inflammatory conditions, but not in
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normal physiology. The authors also found that SLC26A9
prevents airway mucous obstruction after stimulation with
IL-13. These changes were due to increased SLC26A9 activity, which may be due to changes in regulation by WNK
kinases [104]. Unlike CFTR and TMEM16A, SLC26A9 is
downregulated in patients with allergic asthma (Figure 4).
Further investigation revealed that a SNP in the 3 UTR of
the SLC26A9 gene likely reduced expression levels in these
patients, possibly through enhanced binding of hsa-miR-632
[120].
SLC26A9 has also been implicated in the pathogenesis
of bronchiectasis, the widening of airways frequently due
to mucous obstruction, a condition often seen in patients
with cystic fibrosis. A recent report [119] identified two
patients with diffuse idiopathic bronchiectasis who also had
mutations in the SLC26A9 gene. One patient presented with a
mutation in a transmembrane domain of SLC26A9 (V486I);
the patient’s brother was asymptomatic, though he had the
same mutation. The second patient presented with a mutation
in the STAS domain of SLC26A9 (R575W) in addition to the
Fdel508 mutation in CFTR. Coexpression of both mutants in
Xenopus oocytes provided evidence of a decreased interaction
between the SLC26A9 STAS domain and the R domain of
CFTR. It is thought that wild-type SLC26A9, in conjunction
with CFTR loss, may enhance ion conductance and fluid
secretion [121]. Thus, loss of SLC26A9, in the setting of
CFTR loss, may result in reduced airway surface liquid
hydration, mucous blockage, and consequent bronchiectasis.
The authors of the study further narrow the CFTR-SLC26A9
interaction region to a peptide within the STAS domain but
do not confirm that the R575W mutation in this peptide
disrupts the interaction and activation [119]. In contrast, a
second group did not report changes in Cl− transport with
the R575W mutation [122]. As the second patient’s daughter
only carried the Fdel508 mutation and was asymptomatic, the
authors speculate that one mutation in CFTR is not sufficient
to produce the CF phenotype [119]. However, mutations in
modifier genes, such as SLC26A9, may contribute to CF in
those heterozygous for CFTR mutations. Thus, SLC26A9 may
influence phenotypic expression of heterozygous mutations
in ion channels (CFTR, ENaC, and others) involved in airway
surface liquid hydration [119].
Further supporting the modifier gene hypothesis, some
SLC26A9 mutations have been shown to increase the risk
of meconium ileus in patients with CF [123], as well as CFrelated diabetes onset [124] and pancreatic disease severity
[108, 125]. In the case of CFTR and SLC26A9 double mutations, the exact mechanism causing the phenotype must be
further investigated as Cl− transport could be due to altered
CFTR and/or SLC26A9 function or to impaired regulation of
CFTR by SLC26A9 or vice versa [119, 124]. Understanding the
various mechanisms of SLC26A9 mutations will be important
towards developing therapies that can improve lung diseases
such as asthma, CF, and bronchiectasis.

5. Conclusions
Chloride transport proteins play crucial roles in airway
health and disease. On one hand, they contribute to proper
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mucus function by controlling mucus hydration and pH via
controlling chloride and bicarbonate ion transport. On the
other hand, they may play a direct role in mucus synthesis,
secretion, and AHR. Recent animal model studies have
emphasized the crucial role that mucus and mucin proteins
play in innate mucosal immunology. Deletion of MUC5B (the
main secreted mucin protein produced in the airway under
homeostatic conditions) results in impaired mucociliary
clearance and increased microbial infection [126]. Knockout
of CFTR in pig results in airway mucus that is more acidic
and deficient in antimicrobial activity due to loss of defensin
function at low pH [3, 127] and is also deficient in mucociliary
clearance as it remains tethered to secreting cells [128]. This
could be due to improper proteolytic processing of mucin
proteins, since loss of CFTR function in the intestine impairs
𝛽-meprin processing and release of secreted mucins in that
setting [129]. Thus a complete understanding of how these
channels contribute to mucus synthesis, secretion, function,
and mucociliary clearance is required to understand the
impact of modulating their activity.
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